🇺🇸 FDA
Patent

US 11248044

Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11248044 (Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545